QuidelOrtho Cuts Full-Year Guidance Amid China IVD Pricing Headwinds
Event summary
- Total revenue grew 3% YoY to $631M, but excluding China, growth was 6%.
- Labs revenue up 4%, Point of Care surged 16%, while Immunohematology rose 1%.
- GAAP net loss of $93M; adjusted EBITDA margin improved by 310 bps to 20.5%.
- Full-year guidance slashed: revenue now expected at $2.52B–$2.60B (down from $2.70B–$2.75B).
- Free cash flow guidance withdrawn due to working capital impacts.
The big picture
QuidelOrtho's mixed Q2 results highlight the dual pressures of regulatory disruption in China and a softer global respiratory market. While its diversified portfolio showed resilience—with strong Point of Care growth—the guidance cut underscores the strategic challenge of balancing geographic exposure against pricing headwinds. The withdrawal of free cash flow guidance signals operational adjustments ahead, testing execution under tighter financial constraints.
What we're watching
- Regulatory Headwinds
- How China's IVD pricing guidelines will continue to pressure revenue.
- Market Diversification
- Whether QuidelOrtho can sustain 6%+ growth outside China amid global respiratory softness.
- Cash Flow Management
- The pace at which working capital normalization will restore free cash flow visibility.
Related topics